• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

原发感染 6 个月后仍能保持对 SARS-CoV-2 的特异性 T 细胞免疫。

Robust SARS-CoV-2-specific T cell immunity is maintained at 6 months following primary infection.

机构信息

Institute of Immunology and Immunotherapy, University of Birmingham, Birmingham, UK.

Immunisation and Countermeasures Division, National Infection Service, London, UK.

出版信息

Nat Immunol. 2021 May;22(5):620-626. doi: 10.1038/s41590-021-00902-8. Epub 2021 Mar 5.

DOI:10.1038/s41590-021-00902-8
PMID:33674800
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7610739/
Abstract

The immune response to SARS-CoV-2 is critical in controlling disease, but there is concern that waning immunity may predispose to reinfection. We analyzed the magnitude and phenotype of the SARS-CoV-2-specific T cell response in 100 donors at 6 months following infection. T cell responses were present by ELISPOT and/or intracellular cytokine staining analysis in all donors and characterized by predominant CD4 T cell responses with strong interleukin (IL)-2 cytokine expression. Median T cell responses were 50% higher in donors who had experienced a symptomatic infection, indicating that the severity of primary infection establishes a 'set point' for cellular immunity. T cell responses to spike and nucleoprotein/membrane proteins were correlated with peak antibody levels. Furthermore, higher levels of nucleoprotein-specific T cells were associated with preservation of nucleoprotein-specific antibody level although no such correlation was observed in relation to spike-specific responses. In conclusion, our data are reassuring that functional SARS-CoV-2-specific T cell responses are retained at 6 months following infection.

摘要

针对 SARS-CoV-2 的免疫反应对控制疾病至关重要,但人们担心免疫减弱可能使机体易再次感染。我们分析了 100 名感染者在感染后 6 个月时针对 SARS-CoV-2 的特异性 T 细胞反应的幅度和表型。在所有供体中,通过 ELISPOT 和/或细胞内细胞因子染色分析均存在 T 细胞反应,并以强烈的白细胞介素 (IL)-2 细胞因子表达为主导的 CD4 T 细胞反应为特征。在经历有症状感染的供体中,T 细胞反应高 50%,表明原发性感染的严重程度为细胞免疫建立了“设定点”。刺突蛋白和核蛋白/膜蛋白的 T 细胞反应与抗体峰值水平相关。此外,核蛋白特异性 T 细胞水平较高与核蛋白特异性抗体水平的保持相关,尽管在与刺突蛋白特异性反应相关时未观察到这种相关性。总之,我们的数据令人安心,即感染后 6 个月时仍保留有针对 SARS-CoV-2 的功能性特异性 T 细胞反应。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f29e/7610739/0c955da74e06/EMS116982-f005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f29e/7610739/547b24737fd7/EMS116982-f006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f29e/7610739/05ec0685f357/EMS116982-f007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f29e/7610739/8a3bc20ef862/EMS116982-f008.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f29e/7610739/f9f338cf45aa/EMS116982-f001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f29e/7610739/13a325ff5798/EMS116982-f002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f29e/7610739/5182436a396e/EMS116982-f003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f29e/7610739/135b568db085/EMS116982-f004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f29e/7610739/0c955da74e06/EMS116982-f005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f29e/7610739/547b24737fd7/EMS116982-f006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f29e/7610739/05ec0685f357/EMS116982-f007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f29e/7610739/8a3bc20ef862/EMS116982-f008.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f29e/7610739/f9f338cf45aa/EMS116982-f001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f29e/7610739/13a325ff5798/EMS116982-f002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f29e/7610739/5182436a396e/EMS116982-f003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f29e/7610739/135b568db085/EMS116982-f004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f29e/7610739/0c955da74e06/EMS116982-f005.jpg

相似文献

1
Robust SARS-CoV-2-specific T cell immunity is maintained at 6 months following primary infection.原发感染 6 个月后仍能保持对 SARS-CoV-2 的特异性 T 细胞免疫。
Nat Immunol. 2021 May;22(5):620-626. doi: 10.1038/s41590-021-00902-8. Epub 2021 Mar 5.
2
SARS-CoV-2 specific T-cell immunity in COVID-19 convalescent patients and unexposed controls measured by ex vivo ELISpot assay.采用 ex vivo ELISpot assay 检测 COVID-19 恢复期患者和未接触者的 SARS-CoV-2 特异性 T 细胞免疫。
Clin Microbiol Infect. 2021 Jul;27(7):1029-1034. doi: 10.1016/j.cmi.2021.03.010. Epub 2021 Apr 2.
3
Immune Memory in Mild COVID-19 Patients and Unexposed Donors Reveals Persistent T Cell Responses After SARS-CoV-2 Infection.轻度 COVID-19 患者和未暴露供体中的免疫记忆揭示了 SARS-CoV-2 感染后持续的 T 细胞反应。
Front Immunol. 2021 Mar 11;12:636768. doi: 10.3389/fimmu.2021.636768. eCollection 2021.
4
Characterization of humoral and SARS-CoV-2 specific T cell responses in people living with HIV.描述 HIV 感染者的体液免疫和 SARS-CoV-2 特异性 T 细胞应答特征。
Nat Commun. 2021 Oct 5;12(1):5839. doi: 10.1038/s41467-021-26137-7.
5
Assessment of SARS-CoV-2 Immunity in Convalescent Children and Adolescents.评估 SARS-CoV-2 免疫在康复期儿童和青少年中的作用。
Front Immunol. 2021 Dec 17;12:797919. doi: 10.3389/fimmu.2021.797919. eCollection 2021.
6
Phenotypes and Functions of SARS-CoV-2-Reactive T Cells.SARS-CoV-2 反应性 T 细胞的表型和功能。
Mol Cells. 2021 Jun 30;44(6):401-407. doi: 10.14348/molcells.2021.0079.
7
Longitudinal Evaluation of Severe Acute Respiratory Syndrome Coronavirus 2 T-Cell Immunity Over 2 Years Following Vaccination and Infection.接种疫苗和感染后 2 年对严重急性呼吸综合征冠状病毒 2 型 T 细胞免疫的纵向评估。
J Infect Dis. 2024 Sep 23;230(3):e605-e615. doi: 10.1093/infdis/jiae215.
8
Antigen-Specific Adaptive Immunity to SARS-CoV-2 in Acute COVID-19 and Associations with Age and Disease Severity.急性 COVID-19 患者中针对 SARS-CoV-2 的抗原特异性适应性免疫反应,及其与年龄和疾病严重程度的关联。
Cell. 2020 Nov 12;183(4):996-1012.e19. doi: 10.1016/j.cell.2020.09.038. Epub 2020 Sep 16.
9
Characterization of SARS-CoV-2-Specific Humoral and Cellular Immune Responses Induced by Inactivated COVID-19 Vaccines in a Real-World Setting.在真实环境中评估灭活 COVID-19 疫苗诱导的 SARS-CoV-2 特异性体液和细胞免疫应答的特征。
Front Immunol. 2021 Dec 22;12:802858. doi: 10.3389/fimmu.2021.802858. eCollection 2021.
10
Robust and Functional Immune Memory Up to 9 Months After SARS-CoV-2 Infection: A Southeast Asian Longitudinal Cohort.SARS-CoV-2 感染后长达 9 个月的稳健且具有功能性的免疫记忆:一项东南亚纵向队列研究。
Front Immunol. 2022 Feb 3;13:817905. doi: 10.3389/fimmu.2022.817905. eCollection 2022.

引用本文的文献

1
Immune Responses of Dendritic Cells to Zoonotic DNA and RNA Viruses.树突状细胞对人畜共患DNA和RNA病毒的免疫反应
Vet Sci. 2025 Jul 24;12(8):692. doi: 10.3390/vetsci12080692.
2
Highly conserved Betacoronavirus sequences are broadly recognized by human T cells.高度保守的β冠状病毒序列被人类T细胞广泛识别。
Cell. 2025 Jul 30. doi: 10.1016/j.cell.2025.07.015.
3
Kidney Involvement in SARS-CoV-2 Infection: Peritoneal Dialysis as the Preferred Modality.新型冠状病毒肺炎感染中的肾脏受累:腹膜透析作为首选治疗方式

本文引用的文献

1
Adaptive immunity to SARS-CoV-2.对严重急性呼吸综合征冠状病毒2(SARS-CoV-2)的适应性免疫
Oxf Open Immunol. 2020;1(1):iqaa003. doi: 10.1093/oxfimm/iqaa003. Epub 2020 Jul 9.
2
Serological surveillance of SARS-CoV-2: Six-month trends and antibody response in a cohort of public health workers.SARS-CoV-2 的血清学监测:公共卫生工作者队列的六个月趋势和抗体反应。
J Infect. 2021 May;82(5):162-169. doi: 10.1016/j.jinf.2021.03.015. Epub 2021 Mar 22.
3
SARS-CoV-2 Infection Severity Is Linked to Superior Humoral Immunity against the Spike.
Vaccines (Basel). 2025 Jul 2;13(7):723. doi: 10.3390/vaccines13070723.
4
Mechanistic Exploration of Yiqi Zengmian in Regulating the Microenvironment as an Immunopotentiator with the Beijing Bio-Institute of Biological Products Coronavirus Vaccine Based on Transcriptomics and Integrated Serum Pharmacochemistry.基于转录组学和血清药物化学整合技术,以北京生物制品研究所新冠病毒疫苗为基础,对益气增免作为免疫增强剂调节微环境的作用机制进行探索
Pharmaceuticals (Basel). 2025 May 27;18(6):802. doi: 10.3390/ph18060802.
5
Detectable SARS-CoV-2 specific immune responses in recovered unvaccinated individuals 250 days post wild type infection.野生型感染250天后康复的未接种疫苗个体中可检测到的SARS-CoV-2特异性免疫反应。
PLoS One. 2025 Jun 11;20(6):e0325923. doi: 10.1371/journal.pone.0325923. eCollection 2025.
6
Early de novo T cell expansion following SARS-CoV-2 infection predicts favourable clinical and virological outcomes.新型冠状病毒2型(SARS-CoV-2)感染后早期的新生T细胞扩增预示着良好的临床和病毒学结果。
EBioMedicine. 2025 Jun 4;117:105795. doi: 10.1016/j.ebiom.2025.105795.
7
Dysregulated Adaptive Immune Responses to SARS-CoV-2 in Immunocompromised Individuals.免疫功能低下个体对SARS-CoV-2的适应性免疫反应失调。
Microorganisms. 2025 May 6;13(5):1077. doi: 10.3390/microorganisms13051077.
8
Hybrid B- and T-Cell Immunity Associates With Protection Against Breakthrough Infection After Severe Acute Respiratory Syndrome Coronavirus 2 Vaccination in Avon Longitudinal Study of Parents and Children (ALSPAC) Participants.在雅芳亲子纵向研究(ALSPAC)参与者中,B细胞和T细胞混合免疫与严重急性呼吸综合征冠状病毒2疫苗接种后预防突破性感染相关。
J Infect Dis. 2025 Aug 14;232(2):e327-e340. doi: 10.1093/infdis/jiaf246.
9
SARS-CoV-2 virus lacking the envelope and membrane open-reading frames as a vaccine platform.缺乏包膜和膜开放阅读框的严重急性呼吸综合征冠状病毒2(SARS-CoV-2)病毒作为一种疫苗平台
Nat Commun. 2025 May 14;16(1):4453. doi: 10.1038/s41467-025-59533-4.
10
Monitoring Immune Responses to Vaccination: A Focus on Single-Cell Analysis and Associated Challenges.监测疫苗接种的免疫反应:聚焦单细胞分析及相关挑战
Vaccines (Basel). 2025 Apr 16;13(4):420. doi: 10.3390/vaccines13040420.
SARS-CoV-2 感染严重程度与针对刺突蛋白的体液免疫优势相关。
mBio. 2021 Jan 19;12(1):e02940-20. doi: 10.1128/mBio.02940-20.
4
Orthogonal SARS-CoV-2 Serological Assays Enable Surveillance of Low-Prevalence Communities and Reveal Durable Humoral Immunity.正交 SARS-CoV-2 血清学检测可用于监测低流行社区,并揭示持久的体液免疫。
Immunity. 2020 Nov 17;53(5):925-933.e4. doi: 10.1016/j.immuni.2020.10.004. Epub 2020 Oct 14.
5
Robust neutralizing antibodies to SARS-CoV-2 infection persist for months.针对 SARS-CoV-2 感染的强大中和抗体可长期存在。
Science. 2020 Dec 4;370(6521):1227-1230. doi: 10.1126/science.abd7728. Epub 2020 Oct 28.
6
Seroprevalence of anti-SARS-CoV-2 antibodies in COVID-19 patients and healthy volunteers up to 6 months post disease onset.新型冠状病毒肺炎患者和健康志愿者发病后 6 个月内抗 SARS-CoV-2 抗体的血清阳性率。
Eur J Immunol. 2020 Dec;50(12):2025-2040. doi: 10.1002/eji.202048970. Epub 2020 Nov 10.
7
What reinfections mean for COVID-19.新冠病毒再感染意味着什么。
Lancet Infect Dis. 2021 Jan;21(1):3-5. doi: 10.1016/S1473-3099(20)30783-0. Epub 2020 Oct 12.
8
Persistence and decay of human antibody responses to the receptor binding domain of SARS-CoV-2 spike protein in COVID-19 patients.COVID-19 患者中针对 SARS-CoV-2 刺突蛋白受体结合域的人抗体反应的持久性和衰减。
Sci Immunol. 2020 Oct 8;5(52). doi: 10.1126/sciimmunol.abe0367.
9
Antigen-Specific Adaptive Immunity to SARS-CoV-2 in Acute COVID-19 and Associations with Age and Disease Severity.急性 COVID-19 患者中针对 SARS-CoV-2 的抗原特异性适应性免疫反应,及其与年龄和疾病严重程度的关联。
Cell. 2020 Nov 12;183(4):996-1012.e19. doi: 10.1016/j.cell.2020.09.038. Epub 2020 Sep 16.
10
Robust T Cell Response Toward Spike, Membrane, and Nucleocapsid SARS-CoV-2 Proteins Is Not Associated with Recovery in Critical COVID-19 Patients.在重症 COVID-19 患者中,针对刺突、膜和核衣壳 SARS-CoV-2 蛋白的稳健 T 细胞反应与恢复无关。
Cell Rep Med. 2020 Sep 22;1(6):100092. doi: 10.1016/j.xcrm.2020.100092. Epub 2020 Aug 29.